Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subjects). Phase 1 is complete and closed for enrollment. It was a multicenter, open-label, dose ranging/dose escalation study that enrolled 9 subjects.
Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subjects). Phase 1 is complete and closed for enrollment. It was a multicenter, open-label, dose ranging/dose escalation study that enrolled 9 subjects.
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
-
Associated Retina Consultants, Phoenix, Arizona, United States, 85020
Vitreo Retinal Associates, P.A., Gainesville, Florida, United States, 32607
Bascom Palmer Eye Institute, Miami, Florida, United States, 33136
Advanced Research, LLC, Pompano Beach, Florida, United States, 33064
Retina Partners Midwest, P.C., Carmel, Indiana, United States, 46032
Boston Children's Hospital, Boston, Massachusetts, United States, 02115
Mississippi Retina Associates, Jackson, Mississippi, United States, 39202
The Retina Institute, Saint Louis, Missouri, United States, 63128
Duke Eye Center, Durham, North Carolina, United States, 27710
Erie Retina Research, LLC, Erie, Pennsylvania, United States, 16505
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
5 Years to
ALL
No
Ocugen,
Murthy Chavali, MD, Ph.D., STUDY_DIRECTOR, Ocugen., Inc.
2026-09-28